Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Trial Profile

An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Colestyramine; Ezetimibe; Fenofibrate; Fluvastatin; Lovastatin; Nicotinic acids; Omega-3-fatty-acid; Pravastatin; Rosuvastatin; Simvastatin
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 29 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 24 Jul 2018 Planned initiation date changed from 14 May 2018 to 3 Aug 2018.
    • 02 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top